RAC Analysis: Race Oncology Appoints BDD Pharma for HARNESS-1 Trial Support

Event: Race Oncology Appoints BDD Pharma for HARNESS-1 Trial Support | Date: 2025-12-27 | Source: Race Oncology Investor Relations

Race Oncology Taps BDD Pharma to Bolster HARNESS-1 Trial Execution

Race Oncology announced on 27 December 2025 the appointment of BDD Pharma as a key partner for its HARNESS-1 clinical trial, focusing on formulation and manufacturing support for the RC220 bisantrene drug product. BDD Pharma, a specialist in pharmaceutical development, will provide expertise in drug formulation, stability testing, and cGMP-compliant manufacturing processes to ensure trial readiness. This move follows recent funding of $3.22 million secured in early December, which fully supports the trial's initiation. The appointment is expected to de-risk supply chain elements, with BDD's involvement starting immediately to align with the planned first patient dosing in Q1 2026. Race highlighted BDD's track record in oncology drug development as a strategic fit for HARNESS-1, aimed at evaluating RC220 in combination with osimertinib for EGFR-mutated non-small cell lung cancer patients. Source: Race Oncology announcement.